West Haven, Connecticut 06516

  • Depression


The goal of this fixed order, open-label, dose-escalation study is to investigate the safety and efficacy of specific doses of dimethyltryptamine (DMT) in humans.

Study summary:

The results of this study will inform the doses to be used in a larger, double-blind, randomized, placebo-controlled, crossover study. Since the goal of the open label study is to inform the double-blind, randomized, placebo-controlled study, the investigators are citing the hypothesis of the latter solely for providing context. The investigators hypothesize that the administration of DMT will result in neuroplastic changes in healthy and depressed subjects. These changes in neuroplasticity will be indexed using electroencephalographic (EEG) measures and tasks. These neuronal changes may in parallel cause changes in mood measured both in healthy and depressed subjects, which will be captured using appropriate psychometric measures of mood.


Healthy controls inclusion criteria: - Medically healthy - Psychiatrically healthy Healthy controls exclusion criteria: - Unstable medical conditions - Psychiatric illness Depression inclusion criteria: - Medically healthy - Diagnosis of major depressive disorder Depression exclusion criteria: -Unstable medical conditions



Primary Contact:

Leigh T Flynn, BS
Phone: 203-932-5711 ext. 2557
Email: leigh.flynn@yale.edu

Backup Contact:


Location Contact:

West Haven, Connecticut 06516
United States

Schizophrenia Research Clinic
Phone: 203-932-5711

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: June 16, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.